Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Por Lassen, Ulrik, Chinot, Olivier L., McBain, Catherine, Mau-Sørensen, Morten, Larsen, Vibeke Andrée, Barrie, Maryline, Roth, Patrick, Krieter, Oliver, Wang, Ka, Habben, Kai, Tessier, Jean, Lahr, Angelika, Weller, Michael
Publicado no Neuro Oncol (2015)

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF...

Por Izar, Benjamin, Sharfman, William, Hodi, F. Stephen, Lawrence, Donald, Flaherty, Keith T., Amaravadi, Ravi, Kim, Kevin B., Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M., Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F., Atkins, Michael B.
Publicado no Cancer Med (2017)

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Por Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L., Datta, Meenal, Song, Jonathan W., Askoxylakis, Vasileios, Taylor, Jennie W., Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D., Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G., Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L., Duda, Dan G., Fukumura, Dai, Batchelor, Tracy T., Jain, Rakesh K.
Publicado no Proc Natl Acad Sci U S A (2016)